Intra-Cellular Therapies Surpasses Analyst Targets: A Deep Dive into Investor Sentiment
In recent trading, shares of Intra-Cellular Therapies Inc (Symbol: ITCI) have exceeded the average analyst 12-month target price of $101.27, currently selling at $127.19 per share. When stocks reach an analyst’s target, there are typically two courses of action: they may downgrade the stock based on its valuation or raise the target price if bullish trends persist. The response from analysts often hinges on the underlying business developments that may have propelled the stock upwards—if positive changes are unfolding, a target price adjustment could be warranted.
The average price target for Intra-Cellular Therapies Inc is derived from the 15 analysts tracked within the Zacks coverage universe. However, this average masks individual ratings, which can vary widely. For instance, one analyst projects a price of $74.00, while another sets their sights as high as $135.00. The standard deviation among these targets stands at $14.088, indicating a broad spectrum of beliefs about the stock’s future.
Investors often look to the average ITCI target price as a collective insight from multiple analysts, rather than relying solely on one opinion. With ITCI’s stock trading above the $101.27 target, it prompts a key question for investors: is this merely a milestone on the way to an even higher target, or has the valuation stretched too thin, suggesting the need to consider reducing their holdings? Below is the current breakdown of analyst ratings for Intra-Cellular Therapies Inc:
| Recent ITCI Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
| Strong buy ratings: | 11 | 11 | 11 | 11 |
| Buy ratings: | 2 | 2 | 2 | 2 |
| Hold ratings: | 2 | 2 | 2 | 2 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.4 | 1.4 | 1.4 | 1.4 |
The average rating, as noted in the table, is based on a scale from 1 to 5, where 1 indicates a Strong Buy and 5 shows a Strong Sell. This article uses data sourced from Zacks Investment Research via Quandl.com. For the latest Zacks research report on ITCI, it’s available for free.
10 ETFs With Most Upside To Analyst Targets »
Additional Resources:
Larry Robbins Stock Picks
ASB market cap history
Top Ten Hedge Funds Holding OVV
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
